Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 6/2010

01-06-2010 | Original Article

Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity

Authors: Hong Lin, Elisa de Stanchina, Xi Kathy Zhou, Feng Hong, Andrew Seidman, Monica Fornier, Wei-Lie Xiao, Edward J. Kennelly, Kathleen Wesa, Barrie R. Cassileth, Susanna Cunningham-Rundles

Published in: Cancer Immunology, Immunotherapy | Issue 6/2010

Login to get access

Abstract

Bone marrow myelotoxicity is a major limitation of chemotherapy. While granulocyte colony stimulating factor (G-CSF) treatment is effective, alternative approaches to support hematopoietic recovery are sought. We previously found that a beta-glucan extract from maitake mushroom Grifola frondosa (MBG) enhanced colony forming unit-granulocyte monocyte (CFU-GM) activity of mouse bone marrow and human hematopoietic progenitor cells (HPC), stimulated G-CSF production and spared HPC from doxorubicin toxicity in vitro. This investigation assessed the effects of MBG on leukocyte recovery and granulocyte/monocyte function in vivo after dose intensive paclitaxel (Ptx) in a normal mouse. After a cumulative dose of Ptx (90–120 mg/kg) given to B6D2F1mice, daily oral MBG (4 or 6 mg/kg), intravenous G-CSF (80 µg/kg) or Ptx alone were compared for effects on the dynamics of leukocyte recovery in blood, CFU-GM activity in bone marrow and spleen, and granulocyte/monocyte production of reactive oxygen species (ROS). Leukocyte counts declined less in Ptx + MBG mice compared to Ptx-alone (p = 0.024) or Ptx + G-CSF treatment (p = 0.031). Lymphocyte levels were higher after Ptx + MBG but not Ptx + G-CSF treatment compared to Ptx alone (p < 0.01). MBG increased CFU-GM activity in bone marrow and spleen (p < 0.001, p = 0.002) 2 days after Ptx. After two additional days (Ptx post-day 4), MBG restored granulocyte/monocyte ROS response to normal levels compared to Ptx-alone and increased ROS response compared to Ptx-alone or Ptx + G-CSF (p < 0.01, both). The studies indicate that oral MBG promoted maturation of HPC to become functionally active myeloid cells and enhanced peripheral blood leukocyte recovery after chemotoxic bone marrow injury.
Appendix
Available only for authorised users
Literature
1.
go back to reference Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439CrossRefPubMed Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439CrossRefPubMed
2.
go back to reference Fornier M, Norton L (2005) Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res 7:64–69CrossRefPubMed Fornier M, Norton L (2005) Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res 7:64–69CrossRefPubMed
3.
go back to reference De Boer RH, Eisen TG, Ellis PA, Johnston SR, Walsh G, Ashley S, Smith IE (2002) A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. Ann Oncol 13:889–894CrossRefPubMed De Boer RH, Eisen TG, Ellis PA, Johnston SR, Walsh G, Ashley S, Smith IE (2002) A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. Ann Oncol 13:889–894CrossRefPubMed
4.
go back to reference Osma MM, Ortuno F, Lozano ML, Gomez-Espuch J, Ayala F, Sanchez-Serrano I, Perez-Ceballos E, Moraleda JM, Vicente V (2001) Administration of post-autologous PBSCT rhG-CSF is associated with long-term low concentrations of bone marrow hematopoietic progenitor cells. Bone Marrow Transplant 27:1287–1292CrossRefPubMed Osma MM, Ortuno F, Lozano ML, Gomez-Espuch J, Ayala F, Sanchez-Serrano I, Perez-Ceballos E, Moraleda JM, Vicente V (2001) Administration of post-autologous PBSCT rhG-CSF is associated with long-term low concentrations of bone marrow hematopoietic progenitor cells. Bone Marrow Transplant 27:1287–1292CrossRefPubMed
5.
go back to reference Pape H, Orth K, Heese A, Heyll A, Kobbe G, Schmitt G, Niederbichler AD, Peiper M, Schwarz A, Boelke E (2006) G-CSF during large field radiotherapy reduces bone marrow recovery capacity. Eur J Med Res 11:322–328PubMed Pape H, Orth K, Heese A, Heyll A, Kobbe G, Schmitt G, Niederbichler AD, Peiper M, Schwarz A, Boelke E (2006) G-CSF during large field radiotherapy reduces bone marrow recovery capacity. Eur J Med Res 11:322–328PubMed
6.
go back to reference Arnedos M, Sutherland S, Ashley S, Smith I (2008) Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer. Breast Cancer Res Treat 112:1–4CrossRefPubMed Arnedos M, Sutherland S, Ashley S, Smith I (2008) Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer. Breast Cancer Res Treat 112:1–4CrossRefPubMed
7.
go back to reference Sugarman S, Wasserheit C, Hodgman E, Coglianese M, D’Alassandro A, Fournier M, Troso-Sandoval T, D’Andrea G, Drullinsky P, Lake D, George R, Mills N, Moynahan M, Smith J, Panageas K, Norton L, Hudis C (2009) A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Res Treat 115:609–612CrossRefPubMed Sugarman S, Wasserheit C, Hodgman E, Coglianese M, D’Alassandro A, Fournier M, Troso-Sandoval T, D’Andrea G, Drullinsky P, Lake D, George R, Mills N, Moynahan M, Smith J, Panageas K, Norton L, Hudis C (2009) A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Res Treat 115:609–612CrossRefPubMed
8.
go back to reference Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642–1649CrossRefPubMed Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642–1649CrossRefPubMed
9.
go back to reference Untch M, Mobus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Luck HJ, Hinke A, Janicke F, Konecny GE (2009) Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 27:2938–2945CrossRefPubMed Untch M, Mobus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Luck HJ, Hinke A, Janicke F, Konecny GE (2009) Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 27:2938–2945CrossRefPubMed
10.
go back to reference Horiguchi J, Rai Y, Tamura K, Taki T, Hisamatsu K, Ito Y, Seriu T, Tajima T (2009) Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan. Anticancer Res 29:625–630PubMed Horiguchi J, Rai Y, Tamura K, Taki T, Hisamatsu K, Ito Y, Seriu T, Tajima T (2009) Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan. Anticancer Res 29:625–630PubMed
11.
go back to reference Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agullo A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G (2009) Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 27:2474–2481CrossRefPubMed Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agullo A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G (2009) Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 27:2474–2481CrossRefPubMed
12.
go back to reference Zhou J, Zhang H, Gu P, Margolick JB, Yin D, Zhang Y (2009) Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model. Breast Cancer Res Treat 115:269–277 Zhou J, Zhang H, Gu P, Margolick JB, Yin D, Zhang Y (2009) Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model. Breast Cancer Res Treat 115:269–277
13.
go back to reference Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP (2009) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 115:87–99CrossRefPubMed Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP (2009) A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 115:87–99CrossRefPubMed
14.
go back to reference Deng G, Lin H, Seidman A, Fornier M, D’Andrea G, Wesa K, Yeung S, Cunningham-Rundles S, Vickers AJ, Cassileth B (2009) A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol 135:1215–1221 Deng G, Lin H, Seidman A, Fornier M, D’Andrea G, Wesa K, Yeung S, Cunningham-Rundles S, Vickers AJ, Cassileth B (2009) A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol 135:1215–1221
16.
go back to reference Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SY, Gordon S (2002) Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 196:407–412CrossRefPubMed Brown GD, Taylor PR, Reid DM, Willment JA, Williams DL, Martinez-Pomares L, Wong SY, Gordon S (2002) Dectin-1 is a major beta-glucan receptor on macrophages. J Exp Med 196:407–412CrossRefPubMed
17.
go back to reference Cramer DE, Allendorf DJ, Baran JT, Hansen R, Marroquin J, Li B, Ratajczak J, Ratajczak MZ, Yan J (2006) Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury. Blood 107:835–840CrossRefPubMed Cramer DE, Allendorf DJ, Baran JT, Hansen R, Marroquin J, Li B, Ratajczak J, Ratajczak MZ, Yan J (2006) Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury. Blood 107:835–840CrossRefPubMed
18.
go back to reference Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J (1999) Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology 42:61–74CrossRefPubMed Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J (1999) Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology 42:61–74CrossRefPubMed
19.
go back to reference Cheung NK, Modak S, Vickers A, Knuckles B (2002) Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 51:557–564PubMed Cheung NK, Modak S, Vickers A, Knuckles B (2002) Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 51:557–564PubMed
20.
go back to reference Harada T, Kawaminami H, Miura NN, Adachi Y, Nakajima M, Yadomae T, Ohno N (2006) Mechanism of enhanced hematopoietic response by soluble beta-glucan SCG in cyclophosphamide-treated mice. Microbiol Immunol 50:687–700PubMed Harada T, Kawaminami H, Miura NN, Adachi Y, Nakajima M, Yadomae T, Ohno N (2006) Mechanism of enhanced hematopoietic response by soluble beta-glucan SCG in cyclophosphamide-treated mice. Microbiol Immunol 50:687–700PubMed
21.
go back to reference Patchen ML, MacVittie TJ, Solberg BD, Souza LM (1990) Survival enhancement and hemopoietic regeneration following radiation exposure: therapeutic approach using glucan and granulocyte colony-stimulating factor. Exp Hematol 18:1042–1048PubMed Patchen ML, MacVittie TJ, Solberg BD, Souza LM (1990) Survival enhancement and hemopoietic regeneration following radiation exposure: therapeutic approach using glucan and granulocyte colony-stimulating factor. Exp Hematol 18:1042–1048PubMed
22.
go back to reference Hofer M, Pospisil M (1997) Glucan as stimulator of hematopoiesis in normal and gamma-irradiated mice. A survey of the authors’ results. Int J Immunopharmacol 19:607–609CrossRefPubMed Hofer M, Pospisil M (1997) Glucan as stimulator of hematopoiesis in normal and gamma-irradiated mice. A survey of the authors’ results. Int J Immunopharmacol 19:607–609CrossRefPubMed
23.
go back to reference Cramer DE, Wagner S, Li B, Liu J, Hansen R, Reca R, Wu W, Surma EZ, Laber DA, Ratajczak MZ, Yan J (2008) Mobilization of hematopoietic progenitor cells by yeast-derived beta-glucan requires activation of matrix metalloproteinase-9. Stem Cells 26:1231–1240CrossRefPubMed Cramer DE, Wagner S, Li B, Liu J, Hansen R, Reca R, Wu W, Surma EZ, Laber DA, Ratajczak MZ, Yan J (2008) Mobilization of hematopoietic progenitor cells by yeast-derived beta-glucan requires activation of matrix metalloproteinase-9. Stem Cells 26:1231–1240CrossRefPubMed
24.
go back to reference Lin H, She YH, Cassileth BR, Sirotnak F, Cunningham Rundles S (2004) Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro. Int Immunopharmacol 4:91–99CrossRefPubMed Lin H, She YH, Cassileth BR, Sirotnak F, Cunningham Rundles S (2004) Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro. Int Immunopharmacol 4:91–99CrossRefPubMed
25.
go back to reference Lin H, Cheung SW, Nesin M, Cassileth BR, Cunningham-Rundles S (2007) Enhancement of umbilical cord blood cell hematopoiesis by maitake beta-glucan is mediated by granulocyte colony-stimulating factor production. Clin Vaccine Immunol 14:21–27CrossRefPubMed Lin H, Cheung SW, Nesin M, Cassileth BR, Cunningham-Rundles S (2007) Enhancement of umbilical cord blood cell hematopoiesis by maitake beta-glucan is mediated by granulocyte colony-stimulating factor production. Clin Vaccine Immunol 14:21–27CrossRefPubMed
26.
go back to reference Lin H, De Stanchina E, Zhou XK, She YH, Hoang D, Cheung SW, Cassileth BR, Cunningham-Rundles S (2009) Maitake beta-glucan enhances umbilical cord blood stem cell transplantation in the NOD/SCID mouse. Exp Biol Med (Maywood) 234:342–353 Lin H, De Stanchina E, Zhou XK, She YH, Hoang D, Cheung SW, Cassileth BR, Cunningham-Rundles S (2009) Maitake beta-glucan enhances umbilical cord blood stem cell transplantation in the NOD/SCID mouse. Exp Biol Med (Maywood) 234:342–353
27.
go back to reference York WS, Darvill AG, McNeil M, Siwenson TT, Albersheim P, Arthur W, Herbert W (1986) Isolation and characterization of plant cell walls and cell wall components. Methods Enzymol 3–40 York WS, Darvill AG, McNeil M, Siwenson TT, Albersheim P, Arthur W, Herbert W (1986) Isolation and characterization of plant cell walls and cell wall components. Methods Enzymol 3–40
28.
go back to reference Merkle RK, Poppe I (1994) Carbohydrate composition analysis of glycoconjugates by gas–liquid chromatography/mass spectrometry. Methods Enzymol 230:1–15CrossRefPubMed Merkle RK, Poppe I (1994) Carbohydrate composition analysis of glycoconjugates by gas–liquid chromatography/mass spectrometry. Methods Enzymol 230:1–15CrossRefPubMed
29.
go back to reference Ballabh P, Simm M, Kumari J, Califano C, Aghai Z, Laborada G, Sison C, Cunningham-Rundles S (2003) Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone. Pediatr Pulmonol 35:392–399CrossRefPubMed Ballabh P, Simm M, Kumari J, Califano C, Aghai Z, Laborada G, Sison C, Cunningham-Rundles S (2003) Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone. Pediatr Pulmonol 35:392–399CrossRefPubMed
30.
go back to reference Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327CrossRefPubMed Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327CrossRefPubMed
31.
go back to reference Eisenhauer EA, Vermorken JB (1998) The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55:5–30CrossRefPubMed Eisenhauer EA, Vermorken JB (1998) The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55:5–30CrossRefPubMed
32.
go back to reference Kim-Park WK, Moore MA, Hakki ZW, Kowolik MJ (1997) Activation of the neutrophil respiratory burst requires both intracellular and extracellular calcium. Ann NY Acad Sci 832:394–404CrossRefPubMed Kim-Park WK, Moore MA, Hakki ZW, Kowolik MJ (1997) Activation of the neutrophil respiratory burst requires both intracellular and extracellular calcium. Ann NY Acad Sci 832:394–404CrossRefPubMed
33.
go back to reference Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T (1998) Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res 58:3331–3338PubMed Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T (1998) Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res 58:3331–3338PubMed
34.
go back to reference Crossin KL, Carney DH (1981) Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 27:341–350CrossRefPubMed Crossin KL, Carney DH (1981) Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 27:341–350CrossRefPubMed
36.
go back to reference Fetterly GJ, Tamburlin JM, Straubinger RM (2001) Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model. Biopharm Drug Dispos 22:251–261CrossRefPubMed Fetterly GJ, Tamburlin JM, Straubinger RM (2001) Paclitaxel pharmacodynamics: application of a mechanism-based neutropenia model. Biopharm Drug Dispos 22:251–261CrossRefPubMed
37.
go back to reference Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 63:1035–1048CrossRefPubMed Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 63:1035–1048CrossRefPubMed
38.
go back to reference Polioudaki H, Kastrinaki MC, Papadaki HA, Theodoropoulos PA (2009) Microtubule-interacting drugs induce moderate and reversible damage to human bone marrow mesenchymal stem cells. Cell Prolif 42:434–447CrossRefPubMed Polioudaki H, Kastrinaki MC, Papadaki HA, Theodoropoulos PA (2009) Microtubule-interacting drugs induce moderate and reversible damage to human bone marrow mesenchymal stem cells. Cell Prolif 42:434–447CrossRefPubMed
39.
go back to reference Panopoulos AD, Watowich SS (2008) Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and ‘emergency’ hematopoiesis. Cytokine 42:277–288CrossRefPubMed Panopoulos AD, Watowich SS (2008) Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and ‘emergency’ hematopoiesis. Cytokine 42:277–288CrossRefPubMed
40.
go back to reference Moore MA, Warren DJ (1987) Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl Acad Sci USA 84:7134–7138CrossRefPubMed Moore MA, Warren DJ (1987) Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice. Proc Natl Acad Sci USA 84:7134–7138CrossRefPubMed
41.
go back to reference Molineux G, Pojda Z, Dexter TM (1990) A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. Blood 75:563–569PubMed Molineux G, Pojda Z, Dexter TM (1990) A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. Blood 75:563–569PubMed
42.
go back to reference Lord BI, Molineux G, Pojda Z, Souza LM, Mermod JJ, Dexter TM (1991) Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood 77:2154–2159PubMed Lord BI, Molineux G, Pojda Z, Souza LM, Mermod JJ, Dexter TM (1991) Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood 77:2154–2159PubMed
43.
go back to reference Rowley SD, Zuehlsdorf M, Braine HG, Colvin OM, Davis J, Jones RJ, Saral R, Sensenbrenner LL, Yeager A, Santos GW (1987) CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Blood 70:271–275PubMed Rowley SD, Zuehlsdorf M, Braine HG, Colvin OM, Davis J, Jones RJ, Saral R, Sensenbrenner LL, Yeager A, Santos GW (1987) CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow. Blood 70:271–275PubMed
44.
go back to reference Lejeune M, Sariban E, Cantinieaux B, Ferster A, Devalck C, Fondu P (1996) Defective polymorphonuclear leukocyte functions in children receiving chemotherapy for cancer are partially restored by recombinant human granulocyte colony-stimulating factor in vitro. J Infect Dis 174:800–805PubMed Lejeune M, Sariban E, Cantinieaux B, Ferster A, Devalck C, Fondu P (1996) Defective polymorphonuclear leukocyte functions in children receiving chemotherapy for cancer are partially restored by recombinant human granulocyte colony-stimulating factor in vitro. J Infect Dis 174:800–805PubMed
45.
go back to reference Lejeune M, Ferster A, Cantinieaux B, Sariban E (1998) Prolonged but reversible neutrophil dysfunctions differentially sensitive to granulocyte colony-stimulating factor in children with acute lymphoblastic leukaemia. Br J Haematol 102:1284–1291CrossRefPubMed Lejeune M, Ferster A, Cantinieaux B, Sariban E (1998) Prolonged but reversible neutrophil dysfunctions differentially sensitive to granulocyte colony-stimulating factor in children with acute lymphoblastic leukaemia. Br J Haematol 102:1284–1291CrossRefPubMed
46.
go back to reference Hubel K, Hegener K, Schnell R, Mansmann G, Oberhauser F, Staib P, Diehl V, Engert A (1999) Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol 78:73–77CrossRefPubMed Hubel K, Hegener K, Schnell R, Mansmann G, Oberhauser F, Staib P, Diehl V, Engert A (1999) Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol 78:73–77CrossRefPubMed
47.
go back to reference Wiles ME, Dykens JA, Wright CD (1994) Regulation of polymorphonuclear leukocyte membrane fluidity: effect of cytoskeletal modification. J Leukoc Biol 56:192–199PubMed Wiles ME, Dykens JA, Wright CD (1994) Regulation of polymorphonuclear leukocyte membrane fluidity: effect of cytoskeletal modification. J Leukoc Biol 56:192–199PubMed
48.
go back to reference Wiles ME, Dykens JA, Wright CD (1995) Human neutrophil (PMN) oxygen radical production and the cytoskeleton. Life Sci 57:1533–1546CrossRefPubMed Wiles ME, Dykens JA, Wright CD (1995) Human neutrophil (PMN) oxygen radical production and the cytoskeleton. Life Sci 57:1533–1546CrossRefPubMed
49.
go back to reference Roberts RL, Nath J, Friedman MM, Gallin JI (1982) Effects of taxol on human neutrophils. J Immunol 129:2134–2141PubMed Roberts RL, Nath J, Friedman MM, Gallin JI (1982) Effects of taxol on human neutrophils. J Immunol 129:2134–2141PubMed
50.
go back to reference Garcia I, Pascual A, Salvador J, Conejo MC, Perea EJ (1996) Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils. J Antimicrob Chemother 38:859–863CrossRefPubMed Garcia I, Pascual A, Salvador J, Conejo MC, Perea EJ (1996) Effect of paclitaxel alone or in combination on the intracellular penetration and activity of quinolones in human neutrophils. J Antimicrob Chemother 38:859–863CrossRefPubMed
51.
go back to reference Boxio R, Bossenmeyer-Pourie C, Steinckwich N, Dournon C, Nusse O (2004) Mouse bone marrow contains large numbers of functionally competent neutrophils. J Leukoc Biol 75:604–611CrossRefPubMed Boxio R, Bossenmeyer-Pourie C, Steinckwich N, Dournon C, Nusse O (2004) Mouse bone marrow contains large numbers of functionally competent neutrophils. J Leukoc Biol 75:604–611CrossRefPubMed
52.
go back to reference Ito K, Masuda Y, Yamasaki Y, Yokota Y, Nanba H (2009) Maitake beta-glucan enhances granulopoiesis and mobilization of granulocytes by increasing G-CSF production and modulating CXCR4/SDF-1 expression. Int Immunopharmacol Ito K, Masuda Y, Yamasaki Y, Yokota Y, Nanba H (2009) Maitake beta-glucan enhances granulopoiesis and mobilization of granulocytes by increasing G-CSF production and modulating CXCR4/SDF-1 expression. Int Immunopharmacol
53.
go back to reference Hoglund M, Hakansson L, Venge P (1997) Effects of in vivo administration of G-CSF on neutrophil functions in healthy volunteers. Eur J Haematol 58:195–202PubMedCrossRef Hoglund M, Hakansson L, Venge P (1997) Effects of in vivo administration of G-CSF on neutrophil functions in healthy volunteers. Eur J Haematol 58:195–202PubMedCrossRef
54.
go back to reference Romero-Benitez MM, Aguirre MV, Juaristi JA, Alvarez MA, Trifaro JM, Brandan NC (2004) In vivo erythroid recovery following paclitaxel injury: correlation between GATA-1, c-MYB, NF-E2, Epo receptor expressions, and apoptosis. Toxicol Appl Pharmacol 194:230–238CrossRefPubMed Romero-Benitez MM, Aguirre MV, Juaristi JA, Alvarez MA, Trifaro JM, Brandan NC (2004) In vivo erythroid recovery following paclitaxel injury: correlation between GATA-1, c-MYB, NF-E2, Epo receptor expressions, and apoptosis. Toxicol Appl Pharmacol 194:230–238CrossRefPubMed
55.
go back to reference Juaristi JA, Aguirre MV, Carmuega RJ, Romero-Benitez M, Alvarez MA, Brandan NC (2001) Hematotoxicity induced by paclitaxel: in vitro and in vivo assays during normal murine hematopoietic recovery. Methods Find Exp Clin Pharmacol 23:161–167CrossRefPubMed Juaristi JA, Aguirre MV, Carmuega RJ, Romero-Benitez M, Alvarez MA, Brandan NC (2001) Hematotoxicity induced by paclitaxel: in vitro and in vivo assays during normal murine hematopoietic recovery. Methods Find Exp Clin Pharmacol 23:161–167CrossRefPubMed
56.
go back to reference Ojeifo JO, Wu AG, Miao Y, Herscowtiz HB, Meehan KR (2000) Docetaxel-induced mobilization of hematopoietic stem cells in a murine model: kinetics, dose titration, and toxicity. Exp Hematol 28:451–459CrossRefPubMed Ojeifo JO, Wu AG, Miao Y, Herscowtiz HB, Meehan KR (2000) Docetaxel-induced mobilization of hematopoietic stem cells in a murine model: kinetics, dose titration, and toxicity. Exp Hematol 28:451–459CrossRefPubMed
57.
go back to reference Churin AA, Gol’dberg VE, Karpova GV, Voronova OL, Feodorova EP, Kolotova OV, Skurikhin EG, Pershina OV (2008) Reaction of bone marrow hematopoiesis to the toxic effect of paclitaxel. Bull Exp Biol Med 145:213–217CrossRefPubMed Churin AA, Gol’dberg VE, Karpova GV, Voronova OL, Feodorova EP, Kolotova OV, Skurikhin EG, Pershina OV (2008) Reaction of bone marrow hematopoiesis to the toxic effect of paclitaxel. Bull Exp Biol Med 145:213–217CrossRefPubMed
58.
go back to reference Pertusini E, Ratajczak J, Majka M, Vaughn D, Ratajczak MZ, Gewirtz AM (2001) Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood 97:638–644CrossRefPubMed Pertusini E, Ratajczak J, Majka M, Vaughn D, Ratajczak MZ, Gewirtz AM (2001) Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood 97:638–644CrossRefPubMed
59.
go back to reference Panaro MA, Mitolo V (1999) Cellular responses to FMLP challenging: a mini-review. Immunopharmacol Immunotoxicol 21:397–419CrossRefPubMed Panaro MA, Mitolo V (1999) Cellular responses to FMLP challenging: a mini-review. Immunopharmacol Immunotoxicol 21:397–419CrossRefPubMed
60.
go back to reference Harler MB, Wakshull E, Filardo EJ, Albina JE, Reichner JS (1999) Promotion of neutrophil chemotaxis through differential regulation of beta 1 and beta 2 integrins. J Immunol 162:6792–6799PubMed Harler MB, Wakshull E, Filardo EJ, Albina JE, Reichner JS (1999) Promotion of neutrophil chemotaxis through differential regulation of beta 1 and beta 2 integrins. J Immunol 162:6792–6799PubMed
61.
go back to reference Lapidot T (2001) Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. the role of SDF-1/CXCR4 interactions. Ann NY Acad Sci 938:83–95PubMed Lapidot T (2001) Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. the role of SDF-1/CXCR4 interactions. Ann NY Acad Sci 938:83–95PubMed
62.
go back to reference Ratajczak MZ, Wysoczynski M, Reca R, Wan W, Zuba-Surma EK, Kucia M, Ratajczak J (2008) A pivotal role of activation of complement cascade (CC) in mobilization of hematopoietic stem/progenitor cells (HSPC). Adv Exp Med Biol 632:47–60PubMed Ratajczak MZ, Wysoczynski M, Reca R, Wan W, Zuba-Surma EK, Kucia M, Ratajczak J (2008) A pivotal role of activation of complement cascade (CC) in mobilization of hematopoietic stem/progenitor cells (HSPC). Adv Exp Med Biol 632:47–60PubMed
63.
go back to reference Winkler IG, Levesque JP (2006) Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Exp Hematol 34:996–1009CrossRefPubMed Winkler IG, Levesque JP (2006) Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Exp Hematol 34:996–1009CrossRefPubMed
64.
go back to reference Reca R, Cramer D, Yan J, Laughlin MJ, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ (2007) A novel role of complement in mobilization: immunodeficient mice are poor granulocyte-colony stimulating factor mobilizers because they lack complement-activating immunoglobulins. Stem Cells 25:3093–3100CrossRefPubMed Reca R, Cramer D, Yan J, Laughlin MJ, Janowska-Wieczorek A, Ratajczak J, Ratajczak MZ (2007) A novel role of complement in mobilization: immunodeficient mice are poor granulocyte-colony stimulating factor mobilizers because they lack complement-activating immunoglobulins. Stem Cells 25:3093–3100CrossRefPubMed
Metadata
Title
Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity
Authors
Hong Lin
Elisa de Stanchina
Xi Kathy Zhou
Feng Hong
Andrew Seidman
Monica Fornier
Wei-Lie Xiao
Edward J. Kennelly
Kathleen Wesa
Barrie R. Cassileth
Susanna Cunningham-Rundles
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0815-3

Other articles of this Issue 6/2010

Cancer Immunology, Immunotherapy 6/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine